Omeros Shares Plunge After EMA Panel Issues Negative Opinion on Yartemlea
Omeros Corporation shares fell sharply after the European Medicines Agency’s CHMP issued a negative opinion on a marketing authorization application for Yartemlea (narsoplimab) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. The company will seek a formal re-examination and review by an Ad Hoc Expert Group, extend…